The purpose of routine axillary lymph node dissection for breast cancer is to remove metastatic lymph nodes, determine the stage, estimate the prognosis, and develop a comprehensive treatment plan. In recent years, the biopsy of the anterior lymph nodes of breast cancer has become one of the hot spots of research because it can accurately assess the status of the axillary lymph nodes, maximize the function of the affected upper limb, reduce the occurrence of lymphedema, and improve the quality of life of patients. The anterior lymph node of breast cancer is the first lymph node to receive lymphatic drainage within the tumor region and to develop tumor metastasis. If this lymph node does not metastasize, the chance of other lymph nodes to develop metastasis is very small, estimated to be less than 5% or lower. Predicting the presence of metastasis in axillary lymph nodes by biopsy of anterior lymph nodes can avoid surgical clearance of axillary lymph nodes without metastasis, reduce postoperative complications such as lymphatic reflux obstructive edema and pain in the affected limb, simplify the surgical procedure, shorten the operative time, and significantly improve the quality of life of breast cancer patients. The American Society of Clinical Oncology has analyzed clinical studies of over 10,000 cases, and the results showed that the sensitivity of sentinel lymph node biopsy ranged from 71% to 100%, with an average false-negative rate of 8.4%. The literature reports false-negative rates of 3.2%-9.7% for the combined Melan and 99TC-SC tracer method. Most investigators agree that using a combination of nuclein and dye as a tracer can achieve complementary results, not only improving the detection rate of anterior lymph nodes, but also reducing the false-negative rate.